Symbols

VERV(Delisted)

Verve Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 3

Revenue Beats Expectation

Price Hits New Low

Price Hits 52-week Low

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About VERV

Verve Therapeutics, Inc.

A clinical-stage biotech company pioneering gene editing therapies for cardiovascular diseases

Industry

Established Date

03/09/2018

Listing Date

06/17/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

274

Fiscal Year Ends

12-31

Website

www.vervetx.com

Security Type

Common stock

Office address

201 Brookline Avenue , Suite 601 , Boston , Massachusetts 02215

Business

Introduction

Verve Therapeutics, Inc., was incorporated as a Delaware corporation on March 9, 2018. The company is a gene drug company that has pioneered a new approach to treating cardiovascular disease, or CVD, transforming the treatment from chronic management to one-way gene editing drugs. The company believes that a single course of treatment can provide significant health benefits over a lifetime for patients with atherosclerotic cardiovascular disease or ASCVD or at risk of atherosclerotic cardiovascular disease.

Company Financials

EPS

VERV has released its 2025 Q1 earnings. EPS was reported at -0.35, versus the expected -0.66, beating expectations. The chart below visualizes how VERV has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

VERV has released its 2025 Q1 earnings report, with revenue of 32.98M, reflecting a YoY change of 479.03%, and net profit of -31.03M, showing a YoY change of 36.32%. The Sankey diagram below clearly presents VERV's revenue sources and cost distribution.